Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients
Phase 1
Terminated
- Conditions
- Non-Hodgkin's Lymphoma
- Registration Number
- NCT00057447
- Lead Sponsor
- InterMune
- Brief Summary
Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL)
International study with sites in the Czech Republic and Poland
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method time to complete response (disappearance of all detectable clinical and radiographic evidenc of disease, and regression of lymph nodes) 6 weeks
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Intermune Inc
🇺🇸Brisbane, California, United States